Difference between revisions of "Age-associated neurodegeneration"

From Aging Chart
Jump to: navigation, search
(Autoloading by CXLParser)
(Autoloading by CXLParser)
 
Line 223: Line 223:
 
(.//.)<html><!--Pop-up for: Alzheimer disease !Pop-up-->
 
(.//.)<html><!--Pop-up for: Alzheimer disease !Pop-up-->
 
<div class="1HWTS9QP3-MXRNMV-12Y" style="display:none;">
 
<div class="1HWTS9QP3-MXRNMV-12Y" style="display:none;">
 +
  
  
Line 234: Line 235:
 
</div>(...)<!--Pop-up for: Protein aggregates !Pop-up-->
 
</div>(...)<!--Pop-up for: Protein aggregates !Pop-up-->
 
<div class="1HWTRDY5Y-1KGPQJM-8G" style="display:none;">
 
<div class="1HWTRDY5Y-1KGPQJM-8G" style="display:none;">
 +
  
  
Line 245: Line 247:
 
</div>(...)<!--Pop-up for: Excess amino acids  !Pop-up-->
 
</div>(...)<!--Pop-up for: Excess amino acids  !Pop-up-->
 
<div class="1HWTSJS2S-1DDC388-191" style="display:none;">
 
<div class="1HWTSJS2S-1DDC388-191" style="display:none;">
 +
  
  
Line 256: Line 259:
 
</div>(...)<!--Pop-up for: IL-1b !Pop-up-->
 
</div>(...)<!--Pop-up for: IL-1b !Pop-up-->
 
<div class="1N9CM8NLV-M9BNQJ-YF4" style="display:none;">
 
<div class="1N9CM8NLV-M9BNQJ-YF4" style="display:none;">
 +
  
  
Line 267: Line 271:
 
</div>(...)<!--Pop-up for: Neurodegeneration !Pop-up-->
 
</div>(...)<!--Pop-up for: Neurodegeneration !Pop-up-->
 
<div class="1HWTS2K9Z-TGM1HN-10H" style="display:none;">
 
<div class="1HWTS2K9Z-TGM1HN-10H" style="display:none;">
 +
  
  
Line 278: Line 283:
 
</div>(...)<!--Pop-up for: Homoplasy of defective mtDNA !Pop-up-->
 
</div>(...)<!--Pop-up for: Homoplasy of defective mtDNA !Pop-up-->
 
<div class="1HX9W0WZH-19M12RQ-15P" style="display:none;">
 
<div class="1HX9W0WZH-19M12RQ-15P" style="display:none;">
 +
  
  
Line 289: Line 295:
 
</div>(...)<!--Pop-up for: IL-6 !Pop-up-->
 
</div>(...)<!--Pop-up for: IL-6 !Pop-up-->
 
<div class="1N9CM7XT7-14T5VT3-YDM" style="display:none;">
 
<div class="1N9CM7XT7-14T5VT3-YDM" style="display:none;">
 +
  
  
Line 300: Line 307:
 
</div>(...)<!--Pop-up for: Autophagy !Pop-up-->
 
</div>(...)<!--Pop-up for: Autophagy !Pop-up-->
 
<div class="1HWTRDK80-1SG3NPM-6F" style="display:none;">
 
<div class="1HWTRDK80-1SG3NPM-6F" style="display:none;">
 +
  
  
Line 311: Line 319:
 
</div>(...)<!--Pop-up for: Lipofuscin  !Pop-up-->
 
</div>(...)<!--Pop-up for: Lipofuscin  !Pop-up-->
 
<div class="1HWTRGL1K-JPKV53-B1" style="display:none;">
 
<div class="1HWTRGL1K-JPKV53-B1" style="display:none;">
 +
  
  
Line 322: Line 331:
 
</div>(...)<!--Pop-up for: IL-2 !Pop-up-->
 
</div>(...)<!--Pop-up for: IL-2 !Pop-up-->
 
<div class="1N9CM8887-TFP7X1-YDW" style="display:none;">
 
<div class="1N9CM8887-TFP7X1-YDW" style="display:none;">
 +
  
  
Line 333: Line 343:
 
</div>(...)<!--Pop-up for: Hangtington's Disease !Pop-up-->
 
</div>(...)<!--Pop-up for: Hangtington's Disease !Pop-up-->
 
<div class="1HWTSBFN1-JV3LQP-156" style="display:none;">
 
<div class="1HWTSBFN1-JV3LQP-156" style="display:none;">
 +
  
  
Line 344: Line 355:
 
</div>(...)<!--Pop-up for: Mitochondrial defects !Pop-up-->
 
</div>(...)<!--Pop-up for: Mitochondrial defects !Pop-up-->
 
<div class="1HXDHW76K-1MK2B56-QZ" style="display:none;">
 
<div class="1HXDHW76K-1MK2B56-QZ" style="display:none;">
 +
  
  
Line 355: Line 367:
 
</div>(...)<!--Pop-up for: Inflammatory  Cytokines !Pop-up-->
 
</div>(...)<!--Pop-up for: Inflammatory  Cytokines !Pop-up-->
 
<div class="1HWTRKQ24-1WXD4Y9-KV" style="display:none;">
 
<div class="1HWTRKQ24-1WXD4Y9-KV" style="display:none;">
 +
  
  
Line 366: Line 379:
 
</div>(...)<!--Pop-up for: Neurons demyelination !Pop-up-->
 
</div>(...)<!--Pop-up for: Neurons demyelination !Pop-up-->
 
<div class="1HWTRTTLJ-SPX8FD-QM" style="display:none;">
 
<div class="1HWTRTTLJ-SPX8FD-QM" style="display:none;">
 +
  
  
Line 377: Line 391:
 
</div>(...)<!--Pop-up for: Insulin resistance !Pop-up-->
 
</div>(...)<!--Pop-up for: Insulin resistance !Pop-up-->
 
<div class="1HWTRZV83-Y57KSW-WL" style="display:none;">
 
<div class="1HWTRZV83-Y57KSW-WL" style="display:none;">
 +
  
  
Line 388: Line 403:
 
</div>(...)<!--Pop-up for: TOR !Pop-up-->
 
</div>(...)<!--Pop-up for: TOR !Pop-up-->
 
<div class="1HWTRXMKL-18FWJSB-TG" style="display:none;">
 
<div class="1HWTRXMKL-18FWJSB-TG" style="display:none;">
 +
  
  
Line 399: Line 415:
 
</div>(...)<!--Pop-up for: IL-4 !Pop-up-->
 
</div>(...)<!--Pop-up for: IL-4 !Pop-up-->
 
<div class="1N9CM8F31-BS5LFT-YF0" style="display:none;">
 
<div class="1N9CM8F31-BS5LFT-YF0" style="display:none;">
 +
  
  
Line 410: Line 427:
 
</div>(...)<!--Pop-up for: Parkinson's Disease !Pop-up-->
 
</div>(...)<!--Pop-up for: Parkinson's Disease !Pop-up-->
 
<div class="1HWTSB297-344VSN-143" style="display:none;">
 
<div class="1HWTSB297-344VSN-143" style="display:none;">
 +
  
  
Line 421: Line 439:
 
</div>(...)<!--Pop-up for: Oxidative stress !Pop-up-->
 
</div>(...)<!--Pop-up for: Oxidative stress !Pop-up-->
 
<div class="1HWTRK8CR-10B0SHS-JB" style="display:none;">
 
<div class="1HWTRK8CR-10B0SHS-JB" style="display:none;">
 +
  
  
Line 432: Line 451:
 
</div>(...)<!--Pop-up for: Apoptosis of neurons !Pop-up-->
 
</div>(...)<!--Pop-up for: Apoptosis of neurons !Pop-up-->
 
<div class="1HWTRHHSP-5MW4YS-CN" style="display:none;">
 
<div class="1HWTRHHSP-5MW4YS-CN" style="display:none;">
 +
  
  
Line 443: Line 463:
 
</div>(...)<!--Pop-up for: IL-12 !Pop-up-->
 
</div>(...)<!--Pop-up for: IL-12 !Pop-up-->
 
<div class="1N9CM82LJ-26Z61H5-YDR" style="display:none;">
 
<div class="1N9CM82LJ-26Z61H5-YDR" style="display:none;">
 +
  
  
Line 454: Line 475:
 
</div>(...)<!--Pop-up for: Metabolic neurons dysfunction !Pop-up-->
 
</div>(...)<!--Pop-up for: Metabolic neurons dysfunction !Pop-up-->
 
<div class="1HWTRVJNH-W2NY0Q-RH" style="display:none;">
 
<div class="1HWTRVJNH-W2NY0Q-RH" style="display:none;">
 +
  
  
Line 465: Line 487:
 
</div>(...)<!--Pop-up for: TNF-a !Pop-up-->
 
</div>(...)<!--Pop-up for: TNF-a !Pop-up-->
 
<div class="1N9CM8T4D-1PXBGJN-YF8" style="display:none;">
 
<div class="1N9CM8T4D-1PXBGJN-YF8" style="display:none;">
 +
  
  

Latest revision as of 10:26, 2 August 2015

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Age-associated neurodegeneration

Neurodegenerative diseases represent a major challenge for today’s society in terms of the large and rapidly increasing number of the people that are afflicted and the general lack of effective treatments. Neurodegeneration is the progressive loss of neuron structure or neuron function, including death of neurons. The term acute neurodegeneration describes clinical conditions in which neurons are rapidly damaged and usually die in response to a sudden insult. This description encompasses stroke, head injury, cerebral or subarachnoid haemorrhage, and ischaemic brain damage derived from fetal or perinatal hypoxia.

Many late-onset neurodegenerative diseases are caused by aggregateprone proteins1 . These diseases, known as proteinopathies, include conditions in which the proteins are predominantly cytosolic (such as Parkinson’s disease, PD, and adult-onset Huntington’s disease, HD), predominantly intranuclear (for example, spinocerebellar ataxia type 1), aggregated in the endoplasmic reticulum (as seen with neuroserpin mutations that cause familial encephalopathy with neuroserpin inclusion bodies) and secreted extracellularly (for example, amyloid-β in Alzheimer’s disease). The capacity to aggregate (although not necessarily the aggregates themselves) is correlated with toxicity. For instance, the point mutations in α-synuclein and tau that cause dominant forms of PD and frontotemporal dementia, respectively, aggregate more rapidly than the wildtype proteins. The same phenomenon is seen with the polyglutamine expansion mutations that cause diseases such as HD — in these diseases earlier onset correlates with longer polyglutamine tracts, and aggregation propensity increases with polyglutamine tract length.

Inflammatory processes have been implicated in both acute and chronic neurodegenerative conditions. The CNS differs in its inflammatory response to other tissues. In general terms, cellular infiltration in the brain in response to inflammation, infection and injury is weaker and delayed, yet many inflammatory responses can be induced rapidly. These include the activation of microglia, and the expression and release of classical inflammatory mediators, such as acute-phase proteins, eicosanoids, complement and cytokines. Cytokines have been implicated as mediators and inhibitors of diverse forms of neurodegeneration. They are induced in response to brain injury and have diverse actions that can cause, exacerbate, mediate and/or inhibit cellular injury and repair.